Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s):  SZLSF

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is focused on improving the early detection and management of cancer and other chronic diseases through diagnostics telehealth programs. Its lead product, Aristotle, is a mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. The Care Oncology Clinic offers a supervised treatment regimen for people diagnosed with cancer of any type or stage. AVRT is a physician-led, telehealth program for identifying and managing the early warning signs of cancer and chronic disease. Its program includes a comprehensive online health evaluation; bloodtests to measure markers of inflammation and metabolism; an initial physician consultation; regular physician follow-up appointments and interval screening. Its additional cancer diagnostics include ColonSentry and the Prostate Health Index.


TSX:SZLS - Post by User

Comment by InvrsContrarianon Mar 03, 2021 2:10pm
84 Views
Post# 32706566

RE:RE:RE:I reached out to investor relations

RE:RE:RE:I reached out to investor relationsI just picked that book that market money suggested by Weinstein and three pages in I'm thinking resistant, trading zones and breakouts. Lol Double digits yup for sure. I'm thinking after uplist. But stops at 6-7 and ten. With pull backs at those levels. I wonder how many investors will cash out because of the coivd revenues and the highs we will see from those earnings and not stay for cancer? They will miss out on the up listing that was voted for at the last AGM. Either nyse or Nasdaq. Both require money in the bank. So pull a MZ and surprise everyone and take what they want. Glta
StockscoutX wrote: It's easy to understand capebretongirl. If StageZero wants a successful launch of Aristotle they are most likely playing by the rules of the institutional investors. I also believe it could be deliberate to keep retailers in the dark so that the SP stagnates and trickles lower so that institutional players could accumulate cheap shares while shaking off retailers with weak hands. When Aristotle launches it will be mainly the instutional investors that will do huge profits with this stock. Moreover, the SP is likely to go in the double digits in the next few months after the launch.


<< Previous
Bullboard Posts
Next >>